Skopos Labs, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $497 Million
- Q2 2025
A detailed history of Skopos Labs, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 212 shares of APLS stock, worth $4,551. This represents 0.0% of its overall portfolio holdings.
Number of Shares
212
Previous 212
-0.0%
Holding current value
$4,551
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
134MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$262 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$255 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$218 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$209 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$193 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.36B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...